JP2015528802A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528802A5
JP2015528802A5 JP2015522098A JP2015522098A JP2015528802A5 JP 2015528802 A5 JP2015528802 A5 JP 2015528802A5 JP 2015522098 A JP2015522098 A JP 2015522098A JP 2015522098 A JP2015522098 A JP 2015522098A JP 2015528802 A5 JP2015528802 A5 JP 2015528802A5
Authority
JP
Japan
Prior art keywords
her2 antibody
fucose
composition according
her2
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015522098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/065189 external-priority patent/WO2014013019A1/en
Publication of JP2015528802A publication Critical patent/JP2015528802A/ja
Publication of JP2015528802A5 publication Critical patent/JP2015528802A5/ja
Pending legal-status Critical Current

Links

JP2015522098A 2012-07-18 2013-07-18 フコシル化が低い抗her2抗体を用いた新規治療処置 Pending JP2015528802A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261673216P 2012-07-18 2012-07-18
US201261673229P 2012-07-18 2012-07-18
US201261673201P 2012-07-18 2012-07-18
US61/673,229 2012-07-18
US61/673,201 2012-07-18
US61/673,216 2012-07-18
EP12197768 2012-12-18
EP12197768.0 2012-12-18
PCT/EP2013/065189 WO2014013019A1 (en) 2012-07-18 2013-07-18 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation

Publications (2)

Publication Number Publication Date
JP2015528802A JP2015528802A (ja) 2015-10-01
JP2015528802A5 true JP2015528802A5 (enExample) 2016-09-08

Family

ID=49948317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015522098A Pending JP2015528802A (ja) 2012-07-18 2013-07-18 フコシル化が低い抗her2抗体を用いた新規治療処置

Country Status (16)

Country Link
US (1) US20150166664A1 (enExample)
EP (1) EP2874658A1 (enExample)
JP (1) JP2015528802A (enExample)
KR (1) KR20150036710A (enExample)
CN (1) CN104394887A (enExample)
AU (1) AU2013291964B2 (enExample)
BR (1) BR112014032169A2 (enExample)
CA (1) CA2875486A1 (enExample)
EA (1) EA201590237A1 (enExample)
IL (1) IL236714A0 (enExample)
MA (1) MA37961A1 (enExample)
MX (1) MX2015000730A (enExample)
NZ (1) NZ701974A (enExample)
SG (1) SG11201407841YA (enExample)
WO (1) WO2014013019A1 (enExample)
ZA (1) ZA201408938B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
JP7273858B2 (ja) * 2018-06-15 2023-05-15 シャンハイ ミラコーケン インコーポレイティド 癌を治療するための方法と材料
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020056338A1 (en) * 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用
CN116942809A (zh) * 2023-03-03 2023-10-27 盛禾(中国)生物制药有限公司 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2026158510A1 (zh) * 2025-01-24 2026-07-30 百奥泰生物制药股份有限公司 治疗实体瘤的联合疗法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
KR101498588B1 (ko) * 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005086875A2 (en) * 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2008028686A2 (en) * 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
MX2012004029A (es) * 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells

Similar Documents

Publication Publication Date Title
US20220306745A1 (en) Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
JP2016536361A5 (enExample)
JP7408396B2 (ja) 併用療法
JP7797875B2 (ja) 癌の治療及び/又は予防のための医薬品
JP2020512281A5 (enExample)
JP2018518454A5 (enExample)
JP2022531408A5 (enExample)
JP2017537105A5 (enExample)
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2018509390A5 (enExample)
JP2021510736A5 (enExample)
JP2016094424A5 (enExample)
JP2016516800A5 (enExample)
JP2019513726A5 (enExample)
JP2018512402A5 (enExample)
JP2014525926A5 (enExample)
JP2013508292A5 (enExample)
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
WO2013024097A1 (en) Combination therapy with an anti - cd19 antibody and a nitrogen mustard
JP2025060639A (ja) Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
JP2023510429A5 (enExample)
JPWO2022270524A5 (enExample)
JP2018529661A5 (enExample)
JP2018533569A5 (enExample)